Effects of HIV protease, nucleoside/non-nucleoside reverse transcriptase inhibitors on Bax, Bcl-2 and apoptosis in two cervical cell lines.

Protease inhibitors (PIs) and reverse transcriptase drugs are important components of highly active antiretroviral therapy (HAART) for treating human acquired immunodeficiency syndrome (AIDS). Long-term clinical therapeutic efficacy and treatment compliance of these agents have been limited by undesirable adverse effects and their oncogenicity has been queried. This study investigated the effects of selected antiretroviral agents on the expression of key apoptotic regulatory genes; Bax and Bcl-2 in two cervical cell lines HCS-2 and NCE16IIA by real-time qPCR gene expression and immunocytochemistry. The anti-apoptotic effects of the PI-LPV/r were investigated by cell death detection ELISA and acridine orange staining. All the antiretroviral drugs and combinations tested had no effects on Bax and Bcl-2 gene expression and protein localisation in both cell lines. The protease inhibitors-LPV/r exhibited significant (P<0.05) inhibition of camptothecin-induced apoptosis in the cervical cancer HCS-2 cell line but not in the normal immortalised NCE16IIA cell line. This anti-apoptotic property of HIV protease inhibitors, although shown so far not to involve protein and RNA synthesis might promote the development of cancer.

[1]  A. Badley.  In vitro and in vivo effects of HIV protease inhibitors on apoptosis , 2005, Cell Death and Differentiation.

[2]  S. Antonov,et al.  A fluorescence vital assay for the recognition and quantification of excitotoxic cell death by necrosis and apoptosis using confocal microscopy on neurons in culture , 2007, Journal of Neuroscience Methods.

[3]  P. Rustin,et al.  Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues , 1999, The Lancet.

[4]  L. Anderson,et al.  Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. , 1997, Journal of the National Cancer Institute.

[5]  Robert H. Shoemaker,et al.  Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo , 2007, Clinical Cancer Research.

[6]  Á. Villanueva,et al.  Fixation and permanent mounting of fluorescent probes after vital labelling of cultured cells. , 2001, Acta histochemica.

[7]  I. Heard.  Prevention of cervical cancer in women with HIV , 2009, Current opinion in HIV and AIDS.

[8]  G. Mortier,et al.  qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data , 2007, Genome Biology.

[9]  D. L. Cook,et al.  Mutagenicity of zidovudine, lamivudine, and abacavir following in vitro exposure of human lymphoblastoid cells or in utero exposure of CD‐1 mice to single agents or drug combinations , 2007, Environmental and molecular mutagenesis.

[10]  A. Badley,et al.  Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. , 2001, Blood.

[11]  S. Bennett,et al.  HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo , 2007, Apoptosis.

[12]  G. Barbarini,et al.  HIV infection and cancer in the era of highly active antiretroviral therapy (Review). , 2007, Oncology reports.

[13]  S. Franceschi,et al.  Pattern of cancer risk in persons with AIDS in Italy in the HAART era , 2009, British Journal of Cancer.

[14]  N. Apostolova,et al.  Enhanced oxidative stress and increased mitochondrial mass during Efavirenz‐induced apoptosis in human hepatic cells , 2010, British journal of pharmacology.

[15]  Z. Desta,et al.  Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth , 2010, HIV medicine.

[16]  B. Gazzard,et al.  Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. M. Stein,et al.  Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. , 2004, AIDS research and human retroviruses.

[18]  D. Andrews,et al.  Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line , 2006, BMC Cancer.

[19]  A. Badley,et al.  HIV protease inhibitors impact on apoptosis. , 2008, Medicinal chemistry (Shariqah (United Arab Emirates)).

[20]  J. Esplugues,et al.  Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells , 2010, Hepatology.

[21]  M. Pallardy,et al.  Apoptosis: Identification of dying cells , 1998, Cell Biology and Toxicology.

[22]  E Borenfreund,et al.  Toxicity determined in vitro by morphological alterations and neutral red absorption. , 1985, Toxicology letters.

[23]  D. Norris,et al.  BMC Biotechnology BioMed Central Methodology article A simple technique for quantifying apoptosis in 96-well plates , 2005 .

[24]  Song Yang,et al.  Discovery and antitumor activities of constituents from Cyrtomium fortumei (J.) Smith rhizomes , 2013, Chemistry Central Journal.

[25]  M. Nguyen,et al.  Non–AIDS-Defining Malignancies in Patients with HIV in the HAART Era , 2010, Current infectious disease reports.

[26]  V. Sahasrabuddhe,et al.  The impact of antiretroviral therapy on HPV and cervical intraepithelial neoplasia: current evidence and directions for future research , 2010, Infectious Agents and Cancer.

[27]  C. Borner,et al.  Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c , 1998, Nature.

[28]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[29]  M. Poirier,et al.  Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells. , 2005, Mutagenesis.

[30]  J. Palefsky.  Human papillomavirus-related disease in people with HIV , 2009, Current opinion in HIV and AIDS.

[31]  J. Esplugues,et al.  Profile of stress and toxicity gene expression in human hepatic cells treated with Efavirenz. , 2012, Antiviral research.

[32]  N. Hessol,et al.  The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. , 2007, American journal of epidemiology.